Compare CYTK & TXRH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CYTK | TXRH |
|---|---|---|
| Founded | 1997 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Restaurants |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.7B | 12.3B |
| IPO Year | 2004 | 2004 |
| Metric | CYTK | TXRH |
|---|---|---|
| Price | $76.84 | $210.39 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 19 | 18 |
| Target Price | $89.26 | ★ $193.78 |
| AVG Volume (30 Days) | ★ 1.7M | 850.4K |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 1.70% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 3.72 |
| Revenue | ★ $13,368,000.00 | N/A |
| Revenue This Year | $7.37 | $13.46 |
| Revenue Next Year | $310.19 | $9.28 |
| P/E Ratio | ★ N/A | $55.83 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $34.60 | $153.83 |
| 52 Week High | $88.31 | $213.26 |
| Indicator | CYTK | TXRH |
|---|---|---|
| Relative Strength Index (RSI) | 45.54 | 68.90 |
| Support Level | $73.95 | $166.34 |
| Resistance Level | $79.66 | $213.26 |
| Average True Range (ATR) | 2.91 | 4.83 |
| MACD | -0.37 | 0.14 |
| Stochastic Oscillator | 33.77 | 98.52 |
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease. The company's product, named as MYQORZO, is an allosteric and reversible inhibitor of cardiac myosin motor activity. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.
Texas Roadhouse Inc is a restaurant company operating predominantly in the casual dining segment. The company manages its restaurant and franchising operations by concept and, as a result, has identified Texas Roadhouse, Bubba's 33, Jaggers, and retail initiatives as separate operating segments. In addition, it has identified Texas Roadhouse and Bubba's 33 as reportable segments. Maximum revenue for the company is generated from the Texas Roadhouse segment, which is a moderately priced, full-service, casual dining restaurant concept offering steaks, a selection of ribs, seafood, chicken, pork chops, pulled pork, vegetable plates, and an assortment of hamburgers, salads, and sandwiches. Geographically, the majority of the firm's restaurants are in the USA, with a few in foreign countries.